Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ziopharm Oncology IN (ZIOP)

Ziopharm Oncology IN (ZIOP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 692,144
  • Shares Outstanding, K 214,286
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,800 K
  • 60-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.97 +8.25%
on 06/15/20
3.80 -15.35%
on 06/25/20
+0.11 (+3.38%)
since 06/05/20
3-Month
2.48 +29.64%
on 05/04/20
3.80 -15.35%
on 06/25/20
+0.69 (+27.58%)
since 04/07/20
52-Week
1.79 +79.11%
on 03/17/20
7.25 -55.66%
on 07/31/19
-2.67 (-45.32%)
since 07/05/19

Most Recent Stories

More News
Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo(R) in Patients with Glioblastoma

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled...

ZIOP : 3.21 (-0.46%)
Do Options Traders Know Something About Ziopharm Oncology (ZIOP) Stock We Don't?

Investors need to pay close attention to Ziopharm Oncology (ZIOP) stock based on the movements in the options market lately.

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board

Ziopharm Oncology, Inc. ("Ziopharm" or "the Company") (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June, M.D., as Chairman of its newly formed Scientific...

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy:...

ZIOP : 3.21 (-0.46%)
SmarTrend Watching for Potential Rebound in Shares of Ziopharm Oncolog After 1.35% Loss

Ziopharm Oncolog (NASDAQ:ZIOP) traded in a range yesterday that spanned from a low of $2.89 to a high of $3.02. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $2.90...

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology

- Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile -

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology Announces Management Transition

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr. Mauney remains a consultant to Ziopharm and will continue to help...

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a virtual fireside chat at the Jefferies 2020...

ZIOP : 3.21 (-0.46%)
Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference

Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the BofA Securities 2020 Health...

ZIOP : 3.21 (-0.46%)
Ziopharm: 1Q Earnings Snapshot

BOSTON (AP) _ Ziopharm Oncology Inc. (ZIOP) on Thursday reported a loss of $18.3 million in its first quarter.

ZIOP : 3.21 (-0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ZIOP with:

Business Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and...

See More

Key Turning Points

2nd Resistance Point 3.32
1st Resistance Point 3.27
Last Price 3.21
1st Support Level 3.17
2nd Support Level 3.13

See More

52-Week High 7.25
Fibonacci 61.8% 5.17
Fibonacci 50% 4.52
Fibonacci 38.2% 3.88
Last Price 3.21
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar